Osteoprotegerin and soluble receptor activator of nuclear factor-κB ligand and risk for coronary events: A nested case-control approach in the prospective EPIC-norfolk population study 1993-2003

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 29, Issue 6, 2009, Pages 975-980

  Semb, Anne G ^a,h   Ueland, Thor ^b   Aukrust, Pål ^b,c   Wareham, Nicholas J ^e   Luben, Robert ^f   Gullestad, Lars ^d   Kastelein, John J P ^g   Khaw, Kay Tee ^f   Boekholdt, S Matthijs ^g  

^a DIAKONHJEMMET HOSPITAL   (Norway)

^b Research Institute for Internal Medicine   (Norway)

^c Section of Clinical Immunology and Infectious Diseases   (Norway)

^d OSLO UNIVERSITY HOSPITAL   (Norway)

^e MRC Epidemiology Unit

^f UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^g Department of Cardiology ^*

^h DIAKONHJEMMET HOSPITAL   (Norway)

Author keywords

Case control study; Coronary artery disease; CRP; Inflammation; Osteoprotegerin; Risk factors

Indexed keywords

OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; TNFRSF11B PROTEIN, HUMAN; TNFSF11 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BONE METABOLISM; CARDIOVASCULAR RISK; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; SEX DIFFERENCE; BLOOD; CASE CONTROL STUDY; HEALTH SURVEY; MIDDLE AGED; RISK ASSESSMENT; RISK FACTOR; TIME; UNITED KINGDOM;

AGED; CASE-CONTROL STUDIES; CORONARY ARTERY DISEASE; ENGLAND; FEMALE; HUMANS; MALE; MIDDLE AGED; OSTEOPROTEGERIN; POPULATION SURVEILLANCE; PROSPECTIVE STUDIES; RANK LIGAND; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS;

EID: 66349101657     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.109.184101     Document Type: Article

References (28)

1. Kiechl S. The osteoprotegerin/RANK/RANKL system: a bone key to vascular disease. Werner P, Knoflach M, Furtner M, Willeit J, Schett G. Expert Rev. Cardiocasc Ther. 2006;4:801-811.
2. Rumberger JA, Simons DB, Fitzpatrick LA, Sheedy PF, Schwartz RS. Coronary artery calcium area by electron-beam computed tomography and coronary atherosclerotic plaque area. A histopathologic correlative study. Circulation. 1995;92:2157-2162.
3. Sandberg WJ, Yndestad A, Oie E, Smith C, Ueland T, Ovchinnikova O, Robertson AK, Muller F, Semb AG, Scholz H, Andreassen AK, Gullestad L, Damas JK, Froland SS, Hansson GK, Halvorsen B, Aukrust P. Enhanced T-cell expression of RANK ligand in acute coronary syndrome: possible role in plaque destabilization. Arterioscler Thromb Vasc Biol. 2006;26:857-863.
4. Jono S, Ikari Y, Shioi A, Mori K, Miki T, Hara K, Nishizawa Y. Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation. 2002;106:1192-1194.
5. Schoppet M, Sattler AM, Schaefer JR, Herzum M, Maisch B, Hofbauer LC. Increased osteoprotegerin serum levels in men with coronary artery disease. J Clin Endocrinol Metab. 2003;88:1024-1028.
6. Browner WS, Lui LY, Cummings SR. Associations of serum osteopro-tegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clin Endocrinol Metab. 2001;86:631-637.
7. Ziegler S, Kudlacek S, Luger A, Minar E. Osteoprotegerin plasma concentrations correlate with severity of peripheral artery disease. Atherosclerosis. 2005;182:175-180.
8. Ueland T, Jemtland R, Godang K, Kjekshus J, Hognestad A, Omland T, Squire IB, Gullestad L, Bollerslev J, Dickstein K, Aukrust P. Prognostic value of osteoprotegerin in heart failure after acute myocardial infarction. J Am Coll Cardiol. 2004;44:1970-1976.
9. Kiechl S, Schett G, Wenning G, Redlich K, Oberhollenzer M, Mayr A, Santer P, Smolen J, Poewe W, Willeit J. Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation. 2004;109:2175-2180.
10. Day N, Oakes S, Luben R, Khaw KT, Bingham S, Welch A, Wareham N. EPIC-Norfolk: study design and characteristics of the cohort. European Prospective Investigation of Cancer. Br J Cancer. 1999;80 Suppl 1:95-103.
11. Boekholdt SM, Peters RJ, Day NE, Luben R, Bingham SA, Wareham NJ, Hack CE, Reitsma PH, Khaw KT. Macrophage migration inhibitory factor and the risk of myocardial infarction or death due to coronary artery disease in adults without prior myocardial infarction or stroke: the EPIC-Norfolk Prospective Population study. Am J Med. 2004;117: 390-397.
12. Boekholdt SM, Kuivenhoven JA, Wareham NJ, Peters RJ, Jukema JW, Luben R, Bingham SA, Day NE, Kastelein JJ, Khaw KT. Plasma levels of cholesteryl ester transfer protein and the risk of future coronary artery disease in apparently healthy men and women: the prospective EPIC- Norfolk population study. Circulation. 2004;110:1418-1423.
13. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
14. Ueland T, Bollerslev J, Godang K, Muller F, Froland SS, Aukrust P. Increased serum osteoprotegerin in disorders characterized by persistent immune activation or glucocorticoid excess-possible role in bone homeostasis. Eur J Endocrinol. 2001;145:685-690.
15. Boekholdt SM, Hack CE, Sandhu MS, Luben R, Bingham SA, Wareham NJ, Peters RJ, Jukema JW, Day NE, Kastelein JJ, Khaw KT. C-reactive protein levels and coronary artery disease incidence and mortality in apparently healthy men and women: the EPIC-Norfolk prospective population study 1993-2003. Atherosclerosis. 2006;187:415-422.
16. Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, Lowe GD, Pepys MB, Gudnason V. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004;350:1387-1397.
17. Ridker PM, Koenig W, Fuster V. C-reactive protein and coronary heart disease. N Engl J Med. 2004;351:295-298.
18. Hofbauer LC, Schoppet M. Osteoprotegerin: a link between osteoporosis and arterial calcification? Lancet. 2001;358:257-259.
19. Brandstrom H, Stiger F, Kahan T, Melhus H, Nystrom F, oHman KP, Malmqvist K, Lind L, Kindmark A. A single nucleotide polymorphism in the promoter region of the osteoprotegerin gene is related to intima-media thickness of the carotid artery in hypertensive patients. The Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA). Blood Press. 2004;13:152-157.
20. Nitta K, Akiba T, Uchida K, Kawashima A, Yumura W, Kabaya T, Nihei H. The progression of vascular calcification and serum osteoprotegerin levels in patients on long-term hemodialysis. Am J Kidney Dis. 2003;42: 303-309.
21. Abedin M, Omland T, Ueland T, Khera A, Aukrust P, Murphy SA, Jain T, Gruntmanis U, McGuire DK, de Lemos JA. Relation of osteoprotegerin to coronary calcium and aortic plaque (from the Dallas Heart Study). Am J Cardiol. 2007;99:513-518.
22. Omland T, Ueland T, Jansson AM, Persson A, Karlsson T, Smith C, Herlitz J, Aukrust P, Hartford M, Caidahl K. Circulating osteoprotegerin levels and long-term prognosis in patients with acute coronary syndromes. J Am Coll Cardiol. 2008;51:627-633.
23. Golledge J, McCann M, Mangan S, Lam A, Karan M. Osteoprotegerin and osteopontin are expressed at high concentrations within symptomatic carotid atherosclerosis. Stroke. 2004;35:1636-1641.
24. Hofbauer LC, Shui C, Riggs BL, Dunstan CR, Spelsberg TC, O'Brien T, Khosla S. Effects of immunosuppressants on receptor activator of NF-kappaB ligand and osteoprotegerin production by human osteoblastic and coronary artery smooth muscle cells. Biochem Biophys Res Commun. 2001;280:334-339.
25. Malyankar UM, Scatena M, Suchland KL, Yun TJ, Clark EA, Giachelli CM. Osteoprotegerin is an alpha vbeta 3-induced, NF-kappa B-dependent survival factor for endothelial cells. J Biol Chem. 2000;275:20959-20962.
26. Mosheimer BA, Kaneider NC, Feistritzer C, Djanani AM, Sturn DH, Patsch JR, Wiedermann CJ. Syndecan-1 is involved in osteoprotegerin-induced chemotaxis in human peripheral blood monocytes. J Clin Endocrinol Metab. 2005;90:2964-2971.
27. Kiechl S, Schett G, Schwaiger J, Seppi K, Eder P, Egger G, Santer P, Mayr A, Xu Q, Willeit J. Soluble receptor activator of nuclear factor-kappa B ligand and risk for cardiovascular disease. Circulation. 2007;116:385-391.
28. Joseph F, Chan BY, Durham BH, Ahmad AM, Vinjamuri S, Gallagher JA, Vora JP, Fraser WD. The circadian rhythm of osteoprotegerin and its association with parathyroid hormone secretion J Clin Endocrinol Metab. 2007;92:3230-3238.